Tevogen (TVGN) Cash from Restructuring (2024)

Tevogen Bio Holdings' (TVGN) quarterly Cash from Restructuring came in at $7.1 million in Q1 2024.

Tevogen (TVGN) Cash from Restructuring (2024) Analysis & Trends

Tevogen Bio Holdings (TVGN) has 1 years of Cash from Restructuring data on file, last reported at $7.1 million in Q1 2024.

Quarterly Cash from Restructuring changed N/A year-over-year to $7.1 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $7.1 million (changed N/A YoY) and the FY2024 annual result came in at $7.1 million, changed N/A from the prior year.
Cash from Restructuring was little changed at $7.1 million in Q1 2024.
In the past five years, Cash from Restructuring ranged from a high of $7.1 million in Q1 2024 to a low of $7.1 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Tevogen	25.62 Mn	25.62 Mn	-

Download Data

Date	Value
Mar 31, 2024	7.10 Mn